# A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)

Source: https://onco.cc/trials/nct07902037/  
OnCo record `nct07902037` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SRN-101 run by Siren Biotechnology, not yet recruiting.

## Summary

A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) is a phase 1/2 interventional study registered as NCT07902037 by Siren Biotechnology, with 40 participants planned, started 2026-12. Conditions recorded: Recurrent High Grade Gliomas, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma and Diffuse Hemispheric Glioma. Interventions recorded: SRN-101.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07902037
- Phase: 1/2
- Setting: A Phase 1/2, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of SRN-101, a Recombinant Adeno-Associated Virus Immunotherapy in Adults With Recurrent High-Grade Glioma
- Sponsor: Siren Biotechnology
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07902037: https://clinicaltrials.gov/study/NCT07902037

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Oligodendroglioma, IDH-mutant and 1p/19q-codeleted](https://onco.cc/cancers/oligodendroglioma/)
- drugs: [SRN-101](https://onco.cc/drugs/srn-101/)
- companies: [Siren Biotechnology](https://onco.cc/companies/siren-biotechnology/)

---
JSON: https://onco.cc/api/v1/entities/nct07902037.json